Experimental brain tumor cocktail targets recurrent glioma

NCT ID NCT04547777

Recruiting now Disease control Sponsor: Darell Bigner Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a combination of two drugs—D2C7-IT and 2141-V11—for adults with recurrent malignant glioma, a serious brain cancer. The drugs are delivered directly into the tumor and nearby lymph areas. The main goal is to check safety and find the right dose in 90 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: D2C7-IT (a targeted toxin) and 2141-V11 (an antibody that boosts immune response)
What this could lead to: If it works, this could point toward a new treatment option for recurrent malignant brain tumors that are hard to treat.
What could go wrong: This is a very early phase 1 trial with only 90 people, focused on safety and dosing. The treatment involves direct brain infusions and a device, which carry risks like brain swelling, infection, or bleeding. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA, MALIGNANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma grade III glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA, MALIGNANT

Contacts and locations

Locations

Duke University Medical Center
RECRUITING

Durham, North Carolina, 27710, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.